Twist Bioscience could benefit as cheaper AI hypothesis generation and validation make physical experiments the bottleneck. It is currently the purest Anthropic-related biotech beneficiary in this view because Twist handles those experiments. More efficient hypothesis work may eventually ease even that bottleneck, but it is too early to give up on the opportunity. x.com 

Twist Bioscience has real explosive upside in the AI science basket because it makes biology programmable. Its Anthropic partnership, with Claude in the loop, is already rerating the stock, and it just opened a wet lab in San Francisco. AI is moving from code into the physical sciences, and despite the jump on Google news, it is still early. x.com 

Twist Bioscience looks more like a bubble than an investment case, even though it could benefit as AI multiplies drug candidates and pushes value up the biotech chain. It led the 2021 biotech bubble and still loses money, so buyers pay for the story, not the business. The same AI thesis is simpler and cheaper to own in vertical market software, through serial acquirers such as Constellation Software and Topicus, which gain more acquisition targets as software gets cheaper to build. x.com 

Twist Bioscience is squeeze material, with a small float and 19% short interest. It is a former IBD sector leader and a rare biotech with revenue. x.com 

The AI-biology narrative in biotech tools has no connection to fundamental growth. Illumina's two-year compounded growth rate is only 2.2%; the narrative is a made-up pump and dump. x.com 

Illumina's disappointing earnings are a negative read for AI drug-discovery stocks. ScorpionFund points to management's tentative 2027 timing for BioInsight becoming more visible in results, despite upbeat AI-product commentary, and names Twist Bioscience among the affected stocks. x.com 

Moderna's mRNA vaccine news and Twist Bioscience's partnership with Anthropic could spark the cancer and genomics theme across treatments, diagnostics and tools, lifting Personalis, Guardant Health, Twist, HTFL, NeoGenomics and genomics stocks broadly. x.com 

AI-biotech leaders are priced at a fraction of what the market pays for chip makers, which defies logic. Bruker holds the No. 1 or 2 spot in most of its portfolio and faces far less long-term competition than a typical 30x-sales chip name, yet trades at 3x sales. Marvell added nearly $100 billion overnight, while Twist, Schrodinger, Bruker and Recursion together are worth under $20 billion. AI gains must become real-world value, and these companies lead much of the AI-bio pipeline. x.com  x.com 

Twist Bioscience is not a bet worth taking at about 25x sales. @FredaDuan's pitch that AI drug discovery makes it a bottleneck trade, with Twist expecting triple-digit growth in AI-enabled drug-discovery orders in FY26 and again in FY27, is clickbait. x.com  x.com 

The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com  x.com  … Show more